Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.71 |
| ▸ | CCND1 | P24385 | 20/20 | 0.71 |
| ▸ | CDK2 | P24941 | 3/20 | 0.70 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.70 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.61 |
| ▸ | STK16 | O75716 | 1/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | BCR | P11274 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | ERCC2 | P18074 | 1/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.61 |
| ▸ | CCND3 | P30281 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115721 | 0.93 | CDK4 (0.81) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL4030131 | 0.90 | CDK4 (0.87) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087379 | 0.89 | CDK4 (0.71) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL4024091 | 0.89 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL4025333 | 0.88 | CDK4 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL12856535 | 0.87 | CDK4 (0.73) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL1115749 | 0.87 | CDK4 (0.70) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL10087362 | 0.87 | CDK4 (0.70) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7665083 | 0.87 | CDK4 (0.71) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7659763 | 0.87 | CDK4 (0.66) | CDK4CCND1CDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097619-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097619-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893057-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786112-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | AGENNIX USA INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7605175-B2 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH AG (DE) | 2009-10-20 | — | — | US | disclosed |
| US-20090209530-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209530-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | GPC BIOTECH, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-7135550-B2 | Compositions and methods for isolating ligand binding polypeptides for a user-specified ligand, and for isolating small molecule ligands for a user-specified target polypeptide using an improved class of hybrid ligand compounds | GPC BIOTECH INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040266854-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040266853-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | GPC BIOTECH, INC. (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040043388-A1 | Three hybrid assay system | GPC BIOTECH AG (DE) | 2004-03-04 | — | — | US | disclosed |
| US-20030165873-A1 | For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance | GPC BIOTECH AG (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266853-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | CDK4 14/4885CCND1 55/4885CDK2 4/4885 |
| US-20030165873-A1 | For isolating ligand binding polypeptides; fusion proteins; drug screening; kits; surface plasmon resonance | MST1R, PLAUR, SPR | CDK4 2673/4885CCND1 4719/4885CDK2 2203/4885 |
| US-20040043388-A1 | Three hybrid assay system | ACKR3, KLK3, TIMCC | CDK4 3168/4885CCND1 4756/4885CDK2 3218/4885 |
| US-20090209530-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES, COMPOSITIONS AND USES RELATED THERETO | CDK1, CCNO, CCNI | CDK4 14/4885CCND1 55/4885CDK2 4/4885 |
| US-20040266854-A1 | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto | CDK1, CCNO, CCNI | CDK4 14/4885CCND1 55/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.